Search Results for: ANTIBODY DRUG CONJUGATES ADC Development
Articles
ANTIBODY DRUG CONJUGATES - ADC Development Using SMARTag(TM) Technology April 1, 2014
Robyn M. Barfield, PhD, and David Rabuka, PhD, say that despite challenges, there has been progress in advancing complex compounds through clinical trials and successfully treating patients, and these bioconjugate compounds include a subset of molecules known as ADCs.
Lonza Extends Collaboration With Major Pharmaceutical Partner for Integrated Commercial Supply of Antibody-Drug Conjugates October 24, 2024
Lonza recently announced a long-term extension of its collaboration with a major global biopharmaceutical partner for commercial-scale manufacture of ADCs....Simtra BioPharma Solutions Expands Capabilities With $14M Investment in ADC Conjugation & Purification Clinical Suite October 8, 2024
Simtra BioPharma Solutions recently announced a $14-million investment to expand its clinical-scale conjugation and purification capabilities for Antibody-Drug Conjugates (ADCs)....Cybrexa Therapeutics Announces First Patient Dosed With First-in-Class Peptide-Drug Conjugate in Phase 2 Trial in Ovarian Cancer October 7, 2024
Cybrexa Therapeutics recently announced the first patient has been dosed in a Phase 2 clinical trial evaluating CBX-12 in patients...Abzena Supplies Clinical Trial Material for Angiex’s Phase 1 Study of First-in-Class TM4SF1-Directed ADC August 9, 2024
Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC) therapies for solid cancers, recently announced that patient dosing has begun for...AC Immune Unveils Novel Therapeutic ADC Technology for Improved Efficacy in Neurodegenerative Diseases July 31, 2024
AC Immune SA recently unveiled a novel class of neurodegenerative disease-fighting drug-candidates called morADC (Morphomer Antibody Drug Conjugate) in an...Bio-Rad Extends Range of Anti-Biotherapeutic Antibodies to Accelerate Antibody Drug Development June 24, 2024
Bio-Rad Laboratories, Inc. recently launched four new anti-idiotypic antibodies to the following drugs: atezolizumab (Tecentriq), avelumab (Bavencio), obinutuzumab (Gazyvaro), and...Sterling Pharma Solutions Expands Bioanalytical Method Development Capabilities June 19, 2024
Sterling Pharma Solutions recently announced it has expanded its bioanalytical services offering at its Deeside, UK, site, which is the...ArriVent Announces Multi-Target ADC Collaboration With Alphamab June 5, 2024
ArriVent BioPharma, Inc. recently announced it has entered into a collaboration agreement with Jiangsu Alphamab Biopharmaceuticals Co., Ltd. to discover,...SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: Going Beyond the Science to Become True Partners June 3, 2024
Contributor Cindy H. Dubin speaks with leading CDMOs about how they are adapting to bio/pharma client needs, their capabilities in handling complex molecules, and how they are transforming from specialist contractors to true partners.
FORMULATION FORUM - Advances in Drug Delivery by Antibody Drug Conjugates (ADCs) June 3, 2024
Shaukat Ali, PhD, and Jim Huang, PhD, focus on two aspects of drug delivery through ADCs. One, where an antibody is conjugated via a ligand with functionalized LNPs carrying cytotoxic drugs; and two, where an antibody is conjugated directly with drug through a linker at the specific site.
GlycoNex & PrecisemAb Sign Technology Licensing Agreement to Advance Development of Novel Anti-Glycan Antibodies for Cancer Therapy May 28, 2024
GlycoNex to advance development of novel pro-antibody cancer drugs that enhance tumor suppression while minimizing off-site binding to healthy tissues to improve safety and tolerability….
Abzena Launches Next-Generation Immunogenicity Tool for De-Risking the Development of Complex Biologics & Bioconjugates April 26, 2024
Abzena recently announced the launch of its enhanced bioassay platform EpiScreen® 2.0, a comprehensive suite of assays that predict and evaluate potential risks of preclinical immunogenicity in protein….
BioNTech & DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate January 31, 2024
BioNTech SE and Duality Biologics recently announced the US FDA granted Fast Track designation for BNT325/DB-1305 for the treatment of patients with platinum-resistant ovarian epithelial cancer….
FORMULATION FORUM – Nanosuspensions - An Enabling Formulation for Improving Solubility & Bioavailability of Drugs December 4, 2023
Jim Huang, PhD, and Shaukat Ali, PhD, focus on the role of excipients and methods for preparation and application of nanosuspensions in injectable, ocular, topical, and oral drug delivery.
Myricx Enters Antibody License Agreement With Biocytogen September 7, 2023
Myricx Bio recently announced an antibody license agreement with Biocytogen Pharmaceuticals (Beijing) Co., Ltd, a global biotech company focusing on the….
OLON Enters ADC Market May 30, 2023
OLON Group recently announced the start of construction of a new facility at its Rodano site (Milan, Italy) which will be entirely dedicated to managing and producing Ultra-Potent compounds, used for example as payloads and payload-linkers for antibody-drug conjugates (ADCs), one of the….
ImmunoGen Announces a Global, Multi-Target License & Option Agreement With Vertex for the Use of ImmunoGen's ADC Technology in the Development of Novel Targeted Conditioning Agents March 1, 2023
ImmunoGen, Inc. recently announced a global, multi-target license and option agreement whereby it granted Vertex Pharmaceuticals rights to conduct research...Ajinomoto & Exelixis Enter License Agreement to Discover & Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer January 10, 2023
Ajinomoto Co., Inc. recently announced a license agreement with Exelixis, Inc. to incorporate AJICAP, Ajinomoto Co.’s proprietary site-specific bioconjugation and linker technologies, in the development of….
Exelixis & Catalent Enter New License Agreement for Three Antibody-Drug Conjugate Programs With the Potential to Accelerate Exelixis’ Biologics Pipeline November 3, 2022
Exelixis, Inc. and Catalent, Inc. recently announced a new license agreement under which Catalent’s Redwood Bioscience subsidiary will grant Exelixis an exclusive license to three target programs with….